"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 3 | 4 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 6 | 9 |
| 2011 | 5 | 1 | 6 |
| 2012 | 5 | 5 | 10 |
| 2013 | 11 | 8 | 19 |
| 2014 | 4 | 5 | 9 |
| 2015 | 1 | 6 | 7 |
| 2016 | 3 | 14 | 17 |
| 2017 | 5 | 7 | 12 |
| 2018 | 4 | 10 | 14 |
| 2019 | 11 | 8 | 19 |
| 2020 | 6 | 8 | 14 |
| 2021 | 14 | 10 | 24 |
| 2022 | 2 | 19 | 21 |
| 2023 | 4 | 13 | 17 |
| 2024 | 16 | 16 | 32 |
| 2025 | 8 | 15 | 23 |
| 2026 | 7 | 5 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Liver transplantation for primary liver cancers in the era of transplant oncology. J Hepatol. 2026 Oct; 85(4):727-739.
-
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 01; 12(9):1008-1017.
-
Neoadjuvant Stereotactic Body Radiotherapy plus Immune Therapy Favorably Remodels the Hepatocellular Carcinoma Tumor Microenvironment. Clin Cancer Res. 2026 Jul 17; 32(14):2885-2897.
-
What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer? J Natl Compr Canc Netw. 2026 Jul; 24(7).
-
Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA). JCO Glob Oncol. 2026 May; 12(5):e2500287.
-
The 2026 American Association for Thoracic Surgery Expert Consensus Document: Evaluation and management of N2+ non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026 Aug; 172(2):450-466.e2.
-
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer. Sci Transl Med. 2026 Apr 22; 18(846):eaec2358.
-
Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response. J Surg Oncol. 2026 Jun; 133(8):1016-1022.
-
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026 May 10; 44(14):1283-1295.
-
A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. Eur J Cardiothorac Surg. 2026 03 10; 68(3).